Nyemission: Idogen förbereder för fas I/IIa-studie Idogen är ett svenskt bioteknikbolag baserat i Lund. Bolaget utvecklar tolerogena cellterapier som gör det möjligt att undvika en oönskad aktivering av kroppens immunsystem. Cellterapin baseras
Noteringar i veckan
Idogen's Historical Milestones - Idogen
Idogen - Crunchbase Company Profile & Funding
biotech | pharma | diagnostics | devices
Idogen AB (publ)
Stories: EIC-funded company Idogen starts trading on Nasdaq First North Growth Market | EIC Community
Idogen's Historical Milestones - Idogen
BioInsights - Bringing advanced therapies to the clinic: the Swedish National ATMP Consortium (CAMP/SWElife ATMP)
Q3 ENG - Idogen
Idogen AB Delårsrapport Januari–September 2019 | Tanalys
Board and Advisors | Ambulero
Idogen - Crunchbase Company Profile & Funding
biotech | pharma | diagnostics | devices
Idogen appoints Anders Karlsson as new CEO - Idogen
Stories: EIC-funded company Idogen starts trading on Nasdaq First North Growth Market | EIC Community
Idogen AB Year-end report
Idogen aktieägargrupp | Facebook
Iodogen | C16H10Cl4N4O2 | ChemSpider
Idogen - Engineering Immune Tolerance
Idogen AB publicerar Årsredovisning för 2018
Investors Home
Annual Report
Idogen AB (publ) Org nr
Idogen's cell technology successfully advanced to large-scale production
PRESS RELEASE IDOGEN AB
